KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Kioxia Targets U.S. Listing as AI Chip Boom Accelerates 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
FedEx Stock Drops After Weak 2026 Earnings Forecast Despite Strong Q4 Results 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
BERKELEY, Calif., Feb. 24, 2016 -- XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of antibody therapeutics, announced the Company will host a conference call on Wednesday, March 9, 2016, at 4:30 p.m. Eastern Standard Time to discuss fourth quarter and full year 2015 financial results and provide an update on its endocrine disease portfolio.
The webcast can be accessed via the Investors & Media section of XOMA's website at http://investors.xoma.com/events.cfm and will be available for replay until close of business on May 9, 2016. Telephone numbers for the live audiocast are 877-369-6589 (U.S./Canada) and 408-337-0122 (international).
About XOMA Corporation
XOMA Corporation is a leader in the discovery and development of therapeutic antibodies. The Company's innovative product candidates result from its expertise in developing ground-breaking monoclonal antibodies, including allosteric antibodies, which have created new opportunities to potentially treat a wide range of human diseases. XOMA's scientific research has produced a portfolio of five endocrine assets, each of which has the opportunity to address multiple indications. The Company's lead product candidate, XOMA 358, is an allosteric monoclonal antibody that reduces insulin receptor activity, which could have a major impact on the treatment of hyperinsulinism. The Company recently initiated Phase 2 development activities for XOMA 358 in patients with congenital hyperinsulinism. For more information, visit www.xoma.com.
CONTACT: Investor Contacts:
Ashleigh Barreto, XOMA
510-204-7482
[email protected]
Juliane Snowden, The Oratorium Group, LLC
[email protected]
Media Contact:
Ryan Flinn, W2O Group
415-946-1059
[email protected]
